We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.30 | 2.16% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 40,456 | 08:00:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
TIDMTRX
Tissue Regenix Group PLC
10 August 2017
Hardman Research: CellRight transforming US growth
CellRight Technologies: Transforming US growth prospects - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since launch of DermaPure, the focus has been on increasing penetration of the US woundcare market to access both in- and out-patient populations, via GPOs and Medicare, respectively. To accelerate growth in the US, TRX has announced the acquisition of CellRight Technologies, which has a synergistic regenerative technology based on bone. To fund the acquisition and provide more working capital, the company has raised GBP40m (gross) of new capital.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/10.08.17-cellright-transforming-us-growth-prospects.pdf
Hot Features
Premium
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPMMTTMBMBBJR
(END) Dow Jones Newswires
August 10, 2017 08:10 ET (12:10 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
